Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Head and Neck Neoplasms 3Melanoma 2Glioblastoma 2Brain Neoplasms 2Advanced Solid Tumor 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ulnar Neuropathies 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Prostatic Hyperplasia 1Peripheral Lung Tumor 1Pain 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Lung Cancer 1Neuroma 1Multiple Myeloma 1Mucositis 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyoma 1Keratosis, Actinic 1Hyperthermia 1Glioma 1

Interventions

nilotinib 50Imatinib Mesylate 48Dasatinib 25bosutinib 18asciminib 17ponatinib 10Homoharringtonine 5Cytarabine 4olverembatinib 3Interferon-alpha 3Decitabine 3tozasertib 2peginterferon alfa-2a 2flumatinib 2fludarabine phosphate 2ON 01910 2Mycophenolic Acid 2Melphalan 2Interferon alpha-2 2Filgrastim 2Cyclophosphamide 2Bone Marrow Transplantation 2BID protein, human 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1troxacitabine 1triciribine 1terameprocol 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Therapeutics × Clear all
NCT05619978 2022-11-17

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Novartis

Completed
200 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡